Published in AIDS Weekly, June 1st, 1998
The peptide, dubbed ALG889, was developed and tested in animal studies by a team of scientists led by Dr. Jack Marchalonis and Dr. Ronald W. Watson, University of Arizona.
Commenting on the results of the animal studies, Marchalonis said, "When this peptide was administered to mice with an AIDS like viral infection (the MAIDS model), it reversed the immunologic abnormality, and prevented opportunistic infections. Human studies...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.